Human Relaxin-2

Serelaxin showed early promise in RELAX-AHF but failed the confirmatory RELAX-AHF-2 trial. Development for heart failure was discontinued.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

RELAX-AHF showed dyspnea relief and a trend toward reduced mortality. The larger RELAX-AHF-2 trial failed to confirm survival benefit. Development was halted.

• Dyspnea relief in acute heart failure in RELAX-AHF
• Anti-fibrotic and vasodilatory properties well characterized
• Possible renal protective effects observed

RELAX-AHF used 30 mcg/kg/day IV infusion for 48 hours. Not commercially available.

• Hypotension
• Renal impairment at higher doses
• Infusion-site reactions

IV infusion only. Development discontinued after failed phase III. Causes hypotension.

Despite positive phase II signals, the pivotal phase III trial was negative for both primary endpoints.

• Longevity20